For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.

At Dynavax’s third try, an FDA panel favored hepatitis B candidate Heplisav-B's safety profile by a vote of 12 to 1.

Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.

The EU's highest court ruled that EU national courts don't need scientific proof to consider a vaccine as defect.

Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.

A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…

GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.

Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.

Regulatory